Physicians at Jefferson Hospital to Use New Immunotherapy on Brain Tumor Patients

Jefferson Hospital for Neuroscience (JHN) physicians are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient’s tumor with their own cancer cells.

Starting as soon as January 2012, the first of 12 patients diagnosed with a malignant astrocytoma from a clinical trial led by David W. Andrews, MD, co-director of JHN’s Brain Tumor Center of the Kimmel Cancer Center, will receive a “cancer Trojan horse” that could substantially shrink their tumors and possibly extend their lives. For more information, click here to read the full release.